TSMC Obtains 3nm Chip Orders From Broadcom – DigiTimes
Broadcom has placed 3nm chip orders with TSMC joining the foundry's N3 and N3E process customers that include Apple, Qualcomm, MediaTek, Nvidia and AMD, according to industry sources.
Apple Set To Bring Radical Transformation In Chip Industry With Plan To Ditch Broadcom, Qualcomm As Suppliers: Report
Apple Inc. (NASDAQ: AAPL) has been stepping up efforts to diversify away from chip suppliers and use its own silicon in its hardware devices.
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors’ Attention Today
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500 ended in the red.
Here’s How Much You Would Have Made Owning Broadcom Stock In The Last 10 Years
Broadcom (NASDAQ:AVGO) has outperformed the market over the past 10 years by 22.63% on an annualized basis producing…
Broadcom Unusual Options Activity For December 20
A whale with a lot of money to spend has taken a noticeably bearish stance on Broadcom.
Looking at options history for Broadcom (NASDAQ:AVGO) we detected 15 strange trades.
Broadcom’s Target Company VMware Sees 3 Executives Depart As Part Of Restructuring
Three senior VMware, Inc (NYSE: VMW) executives exited the enterprise software company that Broadcom Inc (NASDAQ: AVGO) aims to acquire for $61 billion.
Here’s Where Amgen’s Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022
Amgen Inc's (NASDAQ: AMGN) deal to acquire Horizon Therapeutics (NASDAQ: HZNP) requires a sizable loan that ranks among the biggest debt commitments for
Broadcom’s Vmware Draws More Regulatory Attention, This Time From EU
U.S. chipmaker Broadcom Inc’s (NASDAQ:AVGO) $61 billion Vmware, Inc (NYSE:VMW) deal could hit a roadblock with EU antitrust regulators poised to open…
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session
Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
